Trial Profile

A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LYL 797 (Primary) ; Cyclophosphamide; Fludarabine
Indications Advanced breast cancer; Chronic lymphocytic leukaemia; Endometrial cancer; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Lyell Immunopharma

01 Jul 2025 Status changed from active, no longer recruiting to discontinued due to reprioritization of pipeline.
05 Nov 2024 Status changed from recruiting to active, no longer recruiting.
04 Oct 2024 According to a Lyell Immunopharma media release, translational data from the LYL797 Phase 1 clinical trial will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place in Houston, TX on Friday, Nov. 8, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com